Netherlands· NL-1b5a74b7f83e

Aptivus 100 mg/ml, drank

A tipranavir product containing tipranavir, registered in Netherlands by Boehringer Ingelheim International GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC J05AE09

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about tipranavirAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Tipranavir is registered in 12 of 19 countries.

Countries holding a registration under ATC J05AE09 (tipranavir), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search tipranavir products by name

Tipranavir · ATC J05AE09

12 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tipranavir costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Tipranavir · price per daily dose (1 g)

USD · FX 28 Sept 2026

FR France$30.25

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: TIPRANAVIR
Manufacturer: Boehringer Ingelheim International GmbH
Country: Netherlands (NL)
ATC code: J05AE09
ATC class: Tipranavir
Defined daily dose: 1 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/05/315

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

267 interactions on record for tipranavir.

Graded by severity as the source publishes them — 84 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check tipranavir against other medicines How interaction checks work

Tipranavir · interactions on record

267 records

84 severe
172 moderate
8 info

Most severe, free to view

EluxadolineA07DA06severe
DicoumarolB01AA01severe
WarfarinB01AA03severe
HeparinB01AB01severe

3 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tipranavir in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tipranavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Aptivus
Liechtenstein · Aptivus
Norway · Aptivus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/e2a844e3-2cd2-4c45-94ba-ad875d617429
GET /v1/drugs/e2a844e3-2cd2-4c45-94ba-ad875d617429?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Drank",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/aptivus-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tipranavir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp102492",
  "excipients": [
    "ASCORBINEZUUR (E 300)",
    "BUTTER TOFFEE FLAVOUR PHL-135461 (Givaudan)",
    "BUTTERMINT FLAVOUR 24020",
    "CAPRYL, CAPROYL, CAPRINEZURE MONO, DI, TRIGLYCERIDES",
    "MACROGOL 400",
    "NATUURLIJKE EN KUNSTMATIGE SMAAKSTOFFEN",
    "PROPYLEENGLYCOL (E 1520)",
    "PROPYLEENGLYCOL (E 1520)",
    "SUCRALOSE (E 955)",
    "TOCOFERSOLAN",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "TIPRANAVIR"
  ],
  "leaflet_url": null,
  "authorised_at": "2009/06/23",
  "procedure_number": "EMEA/H/C/000631",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/05/315",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about tipranavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console